Infliximab monotherapy for refractory psoriasis: Preliminary results

International Journal of Immunopathology and Pharmacology

Volumn 17, Issue 3, 2004, Pages 373-380

  Cassano, N ^a   Loconsole, F ^b   Amoruso, A ^b   Coviello, C ^b   Filieri, M ^b   Filotico, R ^b   Del Vecchio, S ^b   Vena, Gino A ^b  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Infliximab; Monotherapy; Psoriasis; Tumour necrosis factor alpha

Indexed keywords

ANTINUCLEAR ANTIBODY; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTHROPATHY; ARTICLE; ASTHENIA; BLOOD CHEMISTRY; BRONCHITIS; CLINICAL ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATOLOGY; HUMAN; HYPERPYREXIA; HYPOTENSION; MALE; MONOTHERAPY; PATHOGENESIS; PATIENT SATISFACTION; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; RELAPSE; SIDE EFFECT; TIME SERIES ANALYSIS;

EID: 8344258333     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200401700317     Document Type: Article

References (39)

1. Zachariae H. 2003. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol. 4:441.
2. Choi J. and J.Y. Koo. 2003. Quality of life issues in psoriasis. J. Am. Acad. Dermatol. 49(S):57.
3. Gottlieb A.B. and J.D. Bos. 2002. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin. Immunol. 105:105.
4. Mehrabi D., J.B. DiCarlo, S.L. Soon and C.O. McCall. 2002. Advances in the management of psoriasis: monoclonal antibody therapies. Int. J. Dermatol. 41:827.
5. Kanitakis J., A.C. Butnaru and A. Claudy. 2003. Novel biological immunotherapies for psoriasis. Expert. Opin. Investig. Drugs. 12:1111.
6. Knight D.M., H. Trinh, J. Le, S. Siegel, D. Shealy, M. McDonough, B. Scallon, M.A. Moore, J. Vilcek, P. Daddona, et al. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 30:1443.
7. Fredriksson T. and U. Pettersson. 1978. Severe psoriasis: Oral therapy with a new retinoid. Dermatologica 157:238.
8. Gottlieb A.B., U. Chaudhari, D.G. Baker, M. Perate and L.T. Dooley. 2003. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J. Drugs Dermatol. 2:260.
9. Nickoloff B.J., G.D. Karabin, J.N. Barker, C.E. Griffiths, V. Sarma, R.S. Mitra, J.T. Elder, S.L. Kunkel and V.M. Dixit. 1991. Cellular localization of interleukin-8 and its inducer, tumor necrosis factor alpha, in psoriasis. Am. J. Pathol. 138:129.
10. Gearing A.J., N.J. Fincham, C.R. Bird, M. Wadhwa, A. Meager, J.E. Cartwright and R.D. Camp. 1990. Cytokines in skin lesions of psoriasis. Cytokine 2:68.
11. Ettehadi P., M.W. Greaves, D. Wallach, D. Aderka and R.D. Camp. 1994. Elevated tumor necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin. Exp. Immunol. 96:146.
12. Partsch G., G. Steiner, B.F. Leeb, A. Dunky, H. Broll and J.S. Smolen. 1997. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol. 24:518.
13. Mussi A., C. Bonifati, M. Carducci, G. D'Agosto, F. Pimpinelli, D. D'Urso, L. D'Auria, M. Fazio and F. Ameglio. 1997. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J. Biol. Regul. Homeost. Agents 11:115.
14. Gottlieb A.B. 2003. Infliximab for psoriasis. J. Am. Acad. Dermatol. 49:S112.
15. Oh C.J., K.M. Das and A.B. Gottlieb. 2000. Treatment with antitumour necrosis factor alpha (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J. Am. Acad. Dermatol. 42:829.
16. Chaudhari U., P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker and A.B. Gottlieb. 2001. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842.
17. Kirby B., A.M. Marsland, A.J. Carmichael and C.E. Griffiths. 2001. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin. Exp. Dermatol. 26:27.
18. Ogilvie A.L., C. Antoni, C. Dechant, B. Manger, J.R. Kalden, G. Schuler and M. Luftl. 2001. Treatment of psoriatic arthritis with antitumour necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. J. Dermatol. 144:587.
19. Schopf R.E., H. Aust and J. Knop. 2002. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor-α, infliximab. J. Am. Acad. Dermatol. 46:886.
20. Wollina U. and H. Konrad. 2002. Treatment of recalcitrant psoriatic arthritis with antitumor necrosis factor-α antibody. J. Eur. Acad. Dermatol. Venereol. 16:127.
21. Mang R., H. Stege, T. Ruzicka and J. Krutmann. 2002. Response of severe psoriasis to infliximab. Dermatology 204:156.
22. Gottlieb A.B., U. Chaudhari, L.D. Mulcahy, S. Li, L.T. Dooley and D.G. Baker. 2003. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J. Am. Acad. Dermatol. 48:829.
23. Chan J.J. and K. Gebauer. 2003. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas. J. Dermatol. 44:116.
24. Gottlieb A.B., S. Masud, R. Ramamurthi, A. Abdulghani, P. Romano, U. Chaudhari, L.T. Dooley, A.A. Fasanmade and C.L. Wagner. 2003. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J. Am. Acad. Dermatol. 48:68.
25. Demidova T.N. and M.R. Hamblin. 2004. Targeted photodynamic therapy to inflammatory cells and pathogens. Int. J. Immunopathol. Pharmacol. 17:117.
26. Appert-Collin A., F.H.T. Duong, P. Passilly-Degrace, J.-P. Gies, J.-M. Warter and P. Poindron. 2004. Quantification of neurotrophin mRNA expression in PMN mouse: modulation by Xaliproden. Int. J. Immunopathol. Pharmacol. 17:157.
27. Pannellini T., M. Iezzi, E. Di Carlo, E. Eleuterio, A. Coletti, A. Modesti, S. Rosini, M. Neri and P. Musiani. 2004. The expression of LEC/CCL16, a powerful inflammatory chemokine, is upregulated in ulcerative colitis. Int. J. Immunopathol. Pharmacol. 17:171.
28. Bellussi L., F. Marcucci, L.G. Sensi, G.C. Passali, M. Lauriello, F.M. Passali, A.L. Giannuzzi and D. Passali. 2004. Do tryptase, ECP and specific IgE measurement by nasal incubation increase the specific nasal provocation test sensitivity? Int. J. Immunopathol. Pharmacol. 17:201.
29. Marchisio M., P.M. Grimley, A. Di Baldassarre, E. Santavenere and S. Miscia. 2004. Novel shift of Jak/Stat signaling characterizes the protective effects of aurintricarboxylic acid (ATA) from tumor necrosis factor-α toxicity in human B lymphocytes. Int. J. Immunopathol. Pharmacol. 17:5.
30. 4 counteracts interleukin-1β and transforming growth factor-β2 synergistic pro-inflammatory activation of human fibroblast-like synoviocytes. Int. J. Immunopathol. Pharmacol. 17:15.
31. Battistoni A., M. Ajello, S. Ammendola, F. Superti, G. Rotilio and P. Valenti. 2004. Involvement of reactive oxygen species in bacterial killing within epithelial cells. Int. J. Immunopathol. Pharmacol. 17:71.
32. Kempuraj D., S. Frydas, P. Conti, K. Kandere, W. Boucher, R. Letourneau, B. Madhappan, S.H. Huang, S. Koreaki, S. Christodoulou and T.C. Theoharides. 2003. Interleukin-25: a new IL-17 family member with growth factor/inflammatory action. Int. J. Immunopathol. Pharmacol. 16:185.
33. Trubiani O., E. Salvolini, R. Staffolani, R. Di Primio and L. Mazzanti. 2003. DMSO modifies structural and functional properties of RPMI-8402 cells by promoting programmed cell death. Int. J. Immunopathol. Pharmacol. 16:253
34. Mastrangelo G., C. Veller Fornasa, S. Pavanello, G. Marcer, M. Lazzaro, G. Milan, E. Fadda, U. Fedeli and E. Clonfero. 2003. Polyaromatic hydrocarbons administered in humans by dermal route increase total IgE. Int. J. Immunopathol. Pharmacol. 16:145.
35. Kerins C.A., R. Spears, L. L. Bellinger and B. Hutchins. 2003. The Prospective Use of COX-2 Inhibitors for the Treatment of Temporomandibular Joint Inflammatory Disorders. Int. J. Immunopathol. Pharmacol. 16(S):1.
36. Ramsay R.G., D. Ciznadija, M. Vanevski and T. Mantamadiotis. 2003. Transcriptional regulation of cyclo-oxygenase expression: three pillars of control. Int. J. Immunopathol. Pharmacol. 16(S):59.
37. Camera E., S. Lisby, M.L. Dell'Anna, B. Santucci, R. Paganelli, O. Baadsgaard and M. Picardo. 2003. Mononuclear cell antioxidant pattern and skin reactivity to irritants. Int. J. Immunopathol. Pharmacol. 16:49.
38. Alexandrakis M.G., D.S. Kyriakou, D. Seretakis, W. Boucher, R. Letourneau, D. Kempuraj and T.C. Theoharides. 2003. Inhibitory effect of retinoic acid on proliferation, maturation and tryptase level in human leukemic mast cells (Hmc-1). Int. J. Immunopathol. Pharmacol. 16:43.
39. Agostini M., B. Di Marco, G. Nocentini and D. V. Delfino. 2002. Oxidative stress and apoptosis in immune diseases. Int. J. Immunopathol. Pharmacol. 15:157.